Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mesenchymal Stem Cells Clear all
Completed Phase 1 Interventional

Adipose Stem Cells for Traumatic Spinal Cord Injury

NCT03308565
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Autologous, Adipose derived Mesenchymal Stem Cells
Biological
Lead sponsor
Mohamad Bydon
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous mesenchymal stem cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 6, 2026, 9:45 PM EDT
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 6, 2026, 9:45 PM EDT
Not listed Phase 1 Interventional

Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

NCT04043819
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PSC-01
Drug
Lead sponsor
Personalized Stem Cells, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Carlsbad, California • La Mesa, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 6, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
View directory record Official record
Conditions
Non Healing Wounds
Interventions
Stem Cell
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 6, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional Results available

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

NCT03857841
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
UNEX-42, Phosphate-buffered saline
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
3 Days to 14 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Not applicable Interventional

Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration

NCT03014037
View directory record Official record
Conditions
Osteoarthritis
Interventions
Unilateral Bone Marrow Procurement, Bilateral Bone Marrow Procurement
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

NCT03529877
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
allo-APZ2-EB
Biological
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
0 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 6, 2026, 9:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 6, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Mesenchymal Stem Cells in Early Rheumatoid Arthritis

NCT03186417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
2 million hMSC/kg, 4 million hMSC/kg, 6 million hMSC/kg, placebo
Biological
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 6, 2026, 9:45 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 6, 2026, 9:45 PM EDT
Recruiting Phase 3 Interventional

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

NCT05354141
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS
Interventions
ExoFlo, Intravenous normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Davis, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 3 Interventional

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

NCT00543374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, PROCHYMAL adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
53
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 6, 2026, 9:45 PM EDT
Suspended Phase 2 Interventional

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

NCT00790764
View directory record Official record
Conditions
Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions
MESENDO, placebo
Biological · Other
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

NCT00361049
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
Biological · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 6, 2026, 9:45 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 6, 2026, 9:45 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

NCT03838250
View directory record Official record
Conditions
Alcoholic Liver Cirrhosis
Interventions
Cellgram™ (Bone marrow-derived MSCs)
Biological
Lead sponsor
Pharmicell Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 6, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

NCT05789394
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
Interventions
Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy, Magnetic Resonance Imaging, Ommaya Reservoir Tap
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Not applicable Interventional

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

NCT04007081
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer
Interventions
Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments
Procedure · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 6, 2026, 9:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging
Other · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)

NCT02589119
View directory record Official record
Conditions
Perianal Fistula, Cryptoglandular Perianal Fistula
Interventions
MSC-AFP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 6, 2026, 9:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

NCT02379442
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
MSC
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 6, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED

NCT02398370
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
Biological
Lead sponsor
Melissa Marchand
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 6, 2026, 9:45 PM EDT